Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia

J. M. I. Vos*, M. C. Minnema, P. W. Wijermans, S. Croockewit, M. E. D. Chamuleau, S. T. Pals, S. K. Klein, M. Delforge, G. W. van Imhoff, M. J. Kersten, HOVON Multiple Myeloma Working, HOVON Lymphoma Working Party

*Corresponding author voor dit werk

Onderzoeksoutputpeer review

22 Citaten (Scopus)
21 Downloads (Pure)


On behalf of the lymphoma and multiple myeloma working parties of the Dutch/Belgian Haemato-Oncology Foundation for Adults in The Netherlands (HOVON), we present a guideline for diagnosis and management of Waldenström's macroglobulinemia (WM). Considering the indolent behaviour and heterogeneous clinical presentation of WM, it is crucial to determine the right indications for treatment, as well as to individualise therapeutic options. There are significant differences from the approach to multiple myeloma or the treatment of other indolent non-Hodkgin lymphomas, and these results cannot always be extrapolated. There is a lack of large clinical trials due to the low incidence of WM. Based on the available data, we provide a practical diagnostic classification, as well as recommendations for first-line therapy and options for treating relapsed disease. Some typical clinical features of WM, such as autoimmune phenomena and 'IgM flare' after rituximab treatment, are highlighted. A more elaborate version of this guideline was published in the 'Nederlands Tijdschrift voor Hematologie' (Dutch Journal for Hematology) September 2012.
Originele taal-2English
Pagina's (van-tot)54-62
Aantal pagina's9
TijdschriftNetherlands Journal of Medicine
Nummer van het tijdschrift2
StatusPublished - mrt.-2013


Duik in de onderzoeksthema's van 'Guideline for diagnosis and treatment of Waldenström's macroglobulinaemia'. Samen vormen ze een unieke vingerafdruk.

Citeer dit